The cornerstone of HA management is replacement therapy; however, this can induce the formation of neutralizing inhibitors, resulting in a refractory FVIII deficiency that is unresponsive to recombinant therapy. The gene discussed is F8; the disease is hyperinsulinemic hypoglycemia, familial, 4.